Gene and splicing therapies for neuromuscular diseases

Frontiers in Bioscience - Landmark

Volumn 20, Issue 8, 2015, Pages 1190-1233

  Benchaouir, Rachid ^a   Robin, Valerie ^a   Goyenvalle, Aurelie ^a  

^a University of Versailles Saint Quentin en Yvelines   (France)

Author keywords

Antisense oligonucleotides; Exon inclusion; Exon skipping; Gene therapy; Neuromuscular disorders; Review; Splicing modulation; Viral vectors

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE;

ADENOVIRIDAE; BIOLOGICAL MODEL; CLINICAL TRIAL (TOPIC); GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; LENTIVIRINAE; NEUROMUSCULAR DISEASES; PATHOLOGY; PROCEDURES; RNA SPLICING; TRANSGENE; TRENDS;

ADENOVIRIDAE; CLINICAL TRIALS AS TOPIC; GENETIC THERAPY; GENETIC VECTORS; HUMANS; LENTIVIRUS; MODELS, GENETIC; NEUROMUSCULAR DISEASES; OLIGONUCLEOTIDES, ANTISENSE; RNA SPLICING; TRANSGENES;

EID: 84949742958     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4367     Document Type: Article

References (251)

1. A. Aartsma-Rus and G. J. van Ommen: Progress in therapeutic antisense applications for neuromuscular disorders. Eur J Hum Genet, 18(2), 146-53 (2010) DOI: 10.1038/ejhg.2009.160
2. S. K. Das, M. E. Menezes, S. Bhatia, X. Y. Wang, L. Emdad, D. Sarkar and P. B. Fisher: Gene therapies for cancer: strategies, challenges and successes. J Cell Physiol (2014)
3. L. Lattanzi, G. Salvatori, M. Coletta, C. Sonnino, M. G. Cusella De Angelis, L. Gioglio, C. E. Murry, R. Kelly, G. Ferrari, M. Molinaro, M. Crescenzi, F. Mavilio and G. Cossu: High efficiency myogenic conversion of human fibroblasts by adenoviral vectormediated MyoD gene transfer. An alternative strategy for ex vivo gene therapy of primary myopathies. J Clin Invest, 101(10), 2119-28 (1998) DOI: 10.1172/JCI1505
4. K. Kawabata, Y. Takakura and M. Hashida: The fate of plasmid DNA after intravenous injection in mice: involvement of scavenger receptors in its hepatic uptake. Pharm Res, 12(6), 825-30 (1995) DOI: 10.1023/A:1016248701505
5. H. Yin, R. L. Kanasty, A. A. Eltoukhy, A. J. Vegas, J. R. Dorkin and D. G. Anderson: Nonviral vectors for gene-based therapy. Nat Rev Genet, 15(8), 541-55 (2014) DOI: 10.1038/nrg3763
6. J. W. Bainbridge, A. J. Smith, S. S. Barker, S. Robbie, R. Henderson, K. Balaggan, A. Viswanathan, G. E. Holder, A. Stockman, N. Tyler, S. Petersen-Jones, S. S. Bhattacharya, A. J. Thrasher, F. W. Fitzke, B. J. Carter, G. S. Rubin, A. T. Moore and R. R. Ali: Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med, 358(21), 2231-9 (2008) DOI: 10.1056/NEJMoa0802268
7. W. W. Hauswirth, T. S. Aleman, S. Kaushal, A. V. Cideciyan, S. B. Schwartz, L. Wang, T. J. Conlon, S. L. Boye, T. R. Flotte, B. J. Byrne and S. G. Jacobson: Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther, 19(10), 979-90 (2008) DOI: 10.1089/hum.2008.107
8. A. M. Maguire, F. Simonelli, E. A. Pierce, E. N. Pugh, Jr., F. Mingozzi, J. Bennicelli, S. Banfi, K. A. Marshall, F. Testa, E. M. Surace, S. Rossi, A. Lyubarsky, V. R. Arruda, B. Konkle, E. Stone, J. Sun, J. Jacobs, L. Dell'Osso, R. Hertle, J. X. Ma, T. M. Redmond, X. Zhu, B. Hauck, O. Zelenaia, K. S. Shindler, M. G. Maguire, J. F. Wright, N. J. Volpe, J. W. McDonnell, A. Auricchio, K. A. High and J. Bennett: Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med, 358(21), 2240-8 (2008) DOI: 10.1056/NEJMoa0802315
9. Y. Yue, A. Ghosh, C. Long, B. Bostick, B. F. Smith, J. N. Kornegay and D. Duan: A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs. Mol Ther, 16(12), 1944-52 (2008) DOI:10.1038/mt.2008.207
10. F. Muntoni, S. Torelli and A. Ferlini: Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol, 2(12), 731-40 (2003) DOI:10.1016/S1474-4422(03) 00585-4
11. K. E. Davies and K. J. Nowak: Molecular mechanisms of muscular dystrophies: old and new players. Nat Rev Mol Cell Biol, 7(10), 762-73 (2006) DOI:10.1038/nrm2024
12. A. E. Emery: The muscular dystrophies. Lancet, 359(9307), 687-95 (2002) DOI:10.1016/S0140-6736(02) 07815-7
13. A. P. Monaco, C. J. Bertelson, S. Liechti-Gallati, H. Moser and L. M. Kunkel: An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics, 2(1), 90-5 (1988) DOI:10.1016/0888-7543(88) 90113-9
14. S. B. England, L. V. Nicholson, M. A. Johnson, S. M. Forrest, D. R. Love, E. E. Zubrzycka-Gaarn, D. E. Bulman, J. B. Harris and K. E. Davies: Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature, 343(6254), 180-2 (1990) DOI:10.1038/343180a0
15. K. Matsumura, A. H. Burghes, M. Mora, F. M. Tome, L. Morandi, F. Cornello, F. Leturcq, M. Jeanpierre, J. C. Kaplan, P. Reinert and et al.: Immunohistochemical analysis of dystrophin-associated proteins in Becker/Duchenne muscular dystrophy with huge in-frame deletions in the NH2-terminal and rod domains of dystrophin. J Clin Invest, 93(1), 99-105 (1994) DOI:10.1172/JCI116989
16. B. Wang, J. Li and X. Xiao: Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Natl Acad Sci U S A, 97(25), 13714-9 (2000) DOI:10.1073/pnas.240335297
17. M. Sakamoto, K. Yuasa, M. Yoshimura, T. Yokota, T. Ikemoto, M. Suzuki, G. Dickson, Y. Miyagoe-Suzuki and S. Takeda: Microdystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene. Biochem Biophys Res Commun, 293(4), 1265-72 (2002) DOI:10.1016/S0006-291X(02) 00362-5
18. S. Q. Harper, M. A. Hauser, C. Dello Russo, D. Duan, R. W. Crawford, S. F. Phelps, H. A. Harper, A. S. Robinson, J. F. Engelhardt, S. V. Brooks and J. S. Chamberlain: Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat Med, 8(3), 253-61 (2002) DOI:10.1038/nm0302-253
19. S. Ogino and R. B. Wilson: Spinal muscular atrophy: molecular genetics and diagnostics. Expert Rev Mol Diagn, 4(1), 15-29 (2004) DOI:10.1586/14737159.4.1.15
20. J. Pearn: Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. J Med Genet, 15(6), 409-13 (1978) DOI:10.1136/jmg.15.6.409
21. S. Lefebvre, L. Burglen, S. Reboullet, O. Clermont, P. Burlet, L. Viollet, B. Benichou, C. Cruaud, P. Millasseau, M. Zeviani and et al.: Identification and characterization of a spinal muscular atrophy-determining gene. Cell, 80(1), 155-65 (1995) DOI:10.1016/0092-8674(95) 90460-3
22. K. D. Foust, E. Nurre, C. L. Montgomery, A. Hernandez, C. M. Chan and B. K. Kaspar: Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol, 27(1), 59-65 (2009) DOI:10.1038/nbt.1515
23. C. F. Valori, K. Ning, M. Wyles, R. J. Mead, A. J. Grierson, P. J. Shaw and M. Azzouz: Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci Transl Med, 2(35), 35ra42 (2010) DOI:10.1126/scitranslmed.3000830
24. L. Naldini, U. Blomer, P. Gallay, D. Ory, R. Mulligan, F. H. Gage, I. M. Verma and D. Trono: In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science, 272(5259), 263-7 (1996) DOI:10.1126/science.272.5259.263
25. P. Kumar and C. Woon-Khiong: Optimization of lentiviral vectors generation for biomedical and clinical research purposes: contemporary trends in technology development and applications. Curr Gene Ther, 11(2), 144-53 (2011) DOI: 10.2174/156652311794940782
26. T. Kafri, U. Blomer, D. A. Peterson, F. H. Gage and I. M. Verma: Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet, 17(3), 314-7 (1997) DOI: 10.1038/ng1197-314
27. E. Kimura, S. Li, P. Gregorevic, B. M. Fall and J. S. Chamberlain: Dystrophin delivery to muscles of mdx mice using lentiviral vectors leads to myogenic progenitor targeting and stable gene expression. Mol Ther, 18(1), 206-13 (2010) DOI:10.1038/mt.2009.253
28. S. Li, E. Kimura, B. M. Fall, M. Reyes, J. C. Angello, R. Welikson, S. D. Hauschka and J. S. Chamberlain: Stable transduction of myogenic cells with lentiviral vectors expressing a minidystrophin. Gene Ther, 12(14), 1099-108 (2005) DOI: 10.1038/sj.gt.3302505
29. G. P. Kobinger, J. P. Louboutin, E. R. Barton, H. L. Sweeney and J. M. Wilson: Correction of the dystrophic phenotype by in vivo targeting of muscle progenitor cells. Hum Gene Ther, 14(15), 1441-9 (2003) DOI: 10.1089/104303403769211655
30. I. J. Fox, G. Q. Daley, S. A. Goldman, J. Huard, T. J. Kamp and M. Trucco: Stem cell therapy. Use of differentiated pluripotent stem cells as replacement therapy for treating disease. Science, 345(6199), 1247391 (2014) DOI: 10.1126/science.1247391
31. R. Benchaouir, M. Meregalli, A. Farini, G. D'Antona, M. Belicchi, A. Goyenvalle, M. Battistelli, N. Bresolin, R. Bottinelli, L. Garcia and Y. Torrente: Restoration of human dystrophin following transplantation of exonskipping-engineered DMD patient stem cells into dystrophic mice. Cell Stem Cell, 1(6), 646-57 (2007) DOI: 10.1016/j.stem.2007.09.016
32. Y. Torrente, M. Belicchi, C. Marchesi, G. D'Antona, F. Cogiamanian, F. Pisati, M. Gavina, R. Giordano, R. Tonlorenzi, G. Fagiolari, C. Lamperti, L. Porretti, R. Lopa, M. Sampaolesi, L. Vicentini, N. Grimoldi, F. Tiberio, V. Songa, P. Baratta, A. Prelle, L. Forzenigo, M. Guglieri, O. Pansarasa, C. Rinaldi, V. Mouly, G. S. Butler-Browne, G. P. Comi, P. Biondetti, M. Moggio, S. M. Gaini, N. Stocchetti, A. Priori, M. G. D'Angelo, A. Turconi, R. Bottinelli, G. Cossu, P. Rebulla and N. Bresolin: Autologous transplantation of muscle-derived CD133+ stem cells in Duchenne muscle patients. Cell Transplant, 16(6), 563-77 (2007) DOI:10.3727/000000007783465064
33. M. Sampaolesi, S. Blot, G. D'Antona, N. Granger, R. Tonlorenzi, A. Innocenzi, P. Mognol, J. L. Thibaud, B. G. Galvez, I. Barthelemy, L. Perani, S. Mantero, M. Guttinger, O. Pansarasa, C. Rinaldi, M. G. Cusella De Angelis, Y. Torrente, C. Bordignon, R. Bottinelli and G. Cossu: Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature, 444(7119), 574-9 (2006) DOI:10.1038/nature05282
34. M. Azzouz, T. Le, G. S. Ralph, L. Walmsley, U. R. Monani, D. C. Lee, F. Wilkes, K. A. Mitrophanous, S. M. Kingsman, A. H. Burghes and N. D. Mazarakis: Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy. J Clin Invest, 114(12), 1726-31 (2004) DOI:10.1172/JCI22922
35. M. Azzouz, G. S. Ralph, E. Storkebaum, L. E. Walmsley, K. A. Mitrophanous, S. M. Kingsman, P. Carmeliet and N. D. Mazarakis: VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature, 429(6990), 413-7 (2004) DOI:10.1038/nature02544
36. W. D. Arnold and A. H. Burghes: Spinal muscular atrophy: development and implementation of potential treatments. Ann Neurol, 74(3), 348-62 (2013)
37. S. Hacein-Bey-Abina, C. Von Kalle, M. Schmidt, M. P. McCormack, N. Wulffraat, P. Leboulch, A. Lim, C. S. Osborne, R. Pawliuk, E. Morillon, R. Sorensen, A. Forster, P. Fraser, J. I. Cohen, G. de Saint Basile, I. Alexander, U. Wintergerst, T. Frebourg, A. Aurias, D. Stoppa-Lyonnet, S. Romana, I. Radford-Weiss, F. Gross, F. Valensi, E. Delabesse, E. Macintyre, F. Sigaux, J. Soulier, L. E. Leiva, M. Wissler, C. Prinz, T. H. Rabbitts, F. Le Deist, A. Fischer and M. Cavazzana-Calvo: LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science, 302(5644), 415-9 (2003) DOI:10.1126/science.1088547
38. J. Cronin, X. Y. Zhang and J. Reiser: Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther, 5(4), 387-98 (2005) DOI:10.2174/1566523054546224
39. R. J. Parks, L. Chen, M. Anton, U. Sankar, M. A. Rudnicki and F. L. Graham: A helperdependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci U S A, 93(24), 13565-70 (1996) DOI:10.1073/pnas.93.24.13565
40. T. Ragot, N. Vincent, P. Chafey, E. Vigne, H. Gilgenkrantz, D. Couton, J. Cartaud, P. Briand, J. C. Kaplan, M. Perricaudet and et al.: Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice. Nature, 361(6413), 647-50 (1993) DOI: 10.1038/361647a0
41. C. Dello Russo, J. M. Scott, D. Hartigan-O'Connor, G. Salvatori, C. Barjot, A. S. Robinson, R. W. Crawford, S. V. Brooks and J. S. Chamberlain: Functional correction of adult mdx mouse muscle using gutted adenoviral vectors expressing full-length dystrophin. Proc Natl Acad Sci U S A, 99(20), 12979-84 (2002) DOI:10.1073/pnas.202300099
42. R. W. Dudley, Y. Lu, R. Gilbert, S. Matecki, J. Nalbantoglu, B. J. Petrof and G. Karpati: Sustained improvement of muscle function one year after full-length dystrophin gene transfer into mdx mice by a gutted helperdependent adenoviral vector. Hum Gene Ther, 15(2), 145-56 (2004) DOI:10.1089/104303404772679959
43. T. Geib and K. J. HerTel: Restoration of fulllength SMN promoted by adenoviral vectors expressing RNA antisense oligonucleotides embedded in U7 snRNAs. PLoS One, 4(12), e8204 (2009) DOI:10.1371/journal.pone.0008204
44. D. A. Muruve, M. J. Barnes, I. E. Stillman and T. A. Libermann: Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum Gene Ther, 10(6), 965-76 (1999) DOI:10.1089/10430349950018364
45. B. Bostick, A. Ghosh, Y. Yue, C. Long and D. Duan: Systemic AAV-9 transduction in mice is influenced by animal age but not by the route of administration. Gene Ther, 14(22), 1605-9 (2007) DOI:10.1038/sj.gt.3303029
46. K. Inagaki, S. Fuess, T. A. Storm, G. A. Gibson, C. F. McTiernan, M. A. Kay and H. Nakai: Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther, 14(1), 45-53 (2006) DOI: 10.1016/j.ymthe.2006.03.014
47. C. A. Pacak, C. S. Mah, B. D. Thattaliyath, T. J. Conlon, M. A. Lewis, D. E. Cloutier, I. Zolotukhin, A. F. Tarantal and B. J. Byrne: Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res, 99(4), e3-9 (2006) DOI:10.1161/01.RES.0000237661.18885.f6
48. R. M. Kotin, M. Siniscalco, R. J. Samulski, X. D. Zhu, L. Hunter, C. A. Laughlin, S. McLaughlin, N. Muzyczka, M. Rocchi and K. I. Berns: Site-specific integration by adenoassociated virus. Proc Natl Acad Sci U S A, 87(6), 2211-5 (1990) DOI:10.1073/pnas.87.6.2211
49. R. J. Samulski, X. Zhu, X. Xiao, J. D. Brook, D. E. Housman, N. Epstein and L. A. Hunter: Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J, 10(12), 3941-50 (1991)
50. A. Srivastava, E. W. Lusby and K. I. Berns: Nucleotide sequence and organization of the adeno-associated virus 2 genome. J Virol, 45(2), 555-64 (1983)
51. K. I. Berns: Parvovirus replication. Microbiol Rev, 54(3), 316-29 (1990)
52. R. J. Samulski, L. S. Chang and T. Shenk: Helper-free stocks of recombinant adenoassociated viruses: normal integration does not require viral gene expression. J Virol, 63(9), 3822-8 (1989)
53. D. Grimm, A. Kern, K. Rittner and J. A. Kleinschmidt: Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum Gene Ther, 9(18), 2745-60 (1998) DOI:10.1089/hum.1998.9.18-2745
54. A. Salvetti, S. Oreve, G. Chadeuf, D. Favre, Y. Cherel, P. Champion-Arnaud, J. David-Ameline and P. Moullier: Factors influencing recombinant adeno-associated virus production. Hum Gene Ther, 9(5), 695-706 (1998) DOI:10.1089/hum.1998.9.5-695
55. X. Xiao, J. Li and R. J. Samulski: Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol, 72(3), 2224-32 (1998)
56. M. Doria, A. Ferrara and A. Auricchio: AAV2/8 vectors purified from culture medium with a simple and rapid protocol transduce murine liver, muscle, and retina efficiently. Hum Gene Ther Methods, 24(6), 392-8 (2013) DOI:10.1089/hgtb.2013.155
57. M. Lock, M. Alvira, L. H. Vandenberghe, A. Samanta, J. Toelen, Z. Debyser and J. M. Wilson: Rapid, simple, and versatile manufacturing of recombinant adenoassociated viral vectors at scale. Hum Gene Ther, 21(10), 1259-71 (2010) DOI:10.1089/hum.2010.055
58. L. H. Vandenberghe, R. Xiao, M. Lock, J. Lin, M. Korn and J. M. Wilson: Efficient serotypedependent release of functional vector into the culture medium during adeno-associated virus manufacturing. Hum Gene Ther, 21(10), 1251-7 (2010) DOI:10.1089/hum.2010.107
59. M. Le Hir, A. Goyenvalle, C. Peccate, G. Precigout, K. E. Davies, T. Voit, L. Garcia and S. Lorain: AAV genome loss from dystrophic mouse muscles during AAV-U7 snRNAmediated exon-skipping therapy. Mol Ther, 21(8), 1551-8 (2013) DOI:10.1038/mt.2013.121
60. M. Urabe, C. Ding and R. M. Kotin: Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum Gene Ther, 13(16), 1935-43 (2002) DOI:10.1089/10430340260355347
61. R. H. Smith, J. R. Levy and R. M. Kotin: A simplified baculovirus-AAV expression vector system coupled with one-step affinity purification yields high-titer rAAV stocks from insect cells. Mol Ther, 17(11), 1888-96 (2009) DOI:10.1038/mt.2009.128
62. D. J. Wasilko, S. E. Lee, K. J. Stutzman-Engwall, B. A. Reitz, T. L. Emmons, K. J. Mathis, M. J. Bienkowski, A. G. Tomasselli and H. D. Fischer: The titerless infected-cells preservation and scale-up (TIPS) method for large-scale production of NO-sensitive human soluble guanylate cyclase (sGC) from insect cells infected with recombinant baculovirus. Protein Expr Purif, 65(2), 122-32 (2009) DOI:10.1016/j.pep.2009.01.002
63. S. Cecchini, T. Virag and R. M. Kotin: Reproducible high yields of recombinant adeno-associated virus produced using invertebrate cells in 0.0.2- to 200-liter cultures. Hum Gene Ther, 22(8), 1021-30 (2011) DOI:10.1089/hum.2010.250
64. P. Gregorevic, J. M. Allen, E. Minami, M. J. Blankinship, M. Haraguchi, L. Meuse, E. Finn, M. E. Adams, S. C. Froehner, C. E. Murry and J. S. Chamberlain: rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med, 12(7), 787-9 (2006) DOI:10.1038/nm1439
65. R. Gilbert, J. Nalbantoglu, J. M. Howell, L. Davies, S. Fletcher, A. Amalfitano, B. J. Petrof, A. Kamen, B. Massie and G. Karpati: Dystrophin expression in muscle following gene transfer with a fully deleted ("gutted") adenovirus is markedly improved by transacting adenoviral gene products. Hum Gene Ther, 12(14), 1741-55 (2001) DOI:10.1089/104303401750476249
66. Z. Wang, C. S. Kuhr, J. M. Allen, M. Blankinship, P. Gregorevic, J. S. Chamberlain, S. J. Tapscott and R. Storb: Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol Ther, 15(6), 1160-6 (2007)
67. T. Koo, T. Okada, T. Athanasopoulos, H. Foster, S. Takeda and G. Dickson: Longterm functional adeno-associated virusmicrodystrophin expression in the dystrophic CXMDj dog. J Gene Med, 13(9), 497-506 (2011) DOI:10.1002/jgm.1602
68. Z. Wang, R. Storb, C. L. Halbert, G. B. Banks, T. M. Butts, E. E. Finn, J. M. Allen, A. D. Miller, J. S. Chamberlain and S. J. Tapscott: Successful regional delivery and long-term expression of a dystrophin gene in canine muscular dystrophy: a preclinical model for human therapies. Mol Ther, 20(8), 1501-7 (2012) DOI:10.1038/mt.2012.111
69. J. H. Shin, Y. Yue, A. Srivastava, B. Smith, Y. Lai and D. Duan: A simplified immune suppression scheme leads to persistent micro-dystrophin expression in Duchenne muscular dystrophy dogs. Hum Gene Ther, 23(2), 202-9 (2012) DOI:10.1089/hum.2011.147
70. J. H. Shin, X. Pan, C. H. Hakim, H. T. Yang, Y. Yue, K. Zhang, R. L. Terjung and D. Duan: Microdystrophin ameliorates muscular dystrophy in the canine model of duchenne muscular dystrophy. Mol Ther, 21(4), 750-7 (2013) DOI:10.1038/mt.2012.283
71. J. R. Mendell, K. Campbell, L. Rodino-Klapac, Z. Sahenk, C. Shilling, S. Lewis, D. Bowles, S. Gray, C. Li, G. Galloway, V. Malik, B. Coley, K. R. Clark, J. Li, X. Xiao, J. Samulski, S. W. McPhee, R. J. Samulski and C. M. Walker: Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med, 363(15), 1429-37 (2010) DOI:10.1056/NEJMoa1000228
72. D. E. Bowles, S. W. McPhee, C. Li, S. J. Gray, J. J. Samulski, A. S. Camp, J. Li, B. Wang, P. E. Monahan, J. E. Rabinowitz, J. C. Grieger, L. Govindasamy, M. Agbandje-McKenna, X. Xiao and R. J. Samulski: Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther, 20(2), 443-55 (2012) DOI:10.1038/mt.2011.237
73. S. Duque, B. Joussemet, C. Riviere, T. Marais, L. Dubreil, A. M. Douar, J. Fyfe, P. Moullier, M. A. Colle and M. Barkats: Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther, 17(7), 1187-96 (2009) DOI:10.1038/mt.2009.71
74. D. M. McCarty: Self-complementary AAV vectors; advances and applications. Mol Ther, 16(10), 1648-56 (2008) DOI:10.1038/mt.2008.171
75. K. D. Foust, X. Wang, V. L. McGovern, L. Braun, A. K. Bevan, A. M. Haidet, T. T. Le, P. R. Morales, M. M. Rich, A. H. Burghes and B. K. Kaspar: Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol, 28(3), 271-4 (2010) DOI:10.1038/nbt.1610
76. A. K. Bevan, K. R. Hutchinson, K. D. Foust, L. Braun, V. L. McGovern, L. Schmelzer, J. G. Ward, J. C. Petruska, P. A. Lucchesi, A. H. Burghes and B. K. Kaspar: Early heart failure in the SMNDelta7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery. Hum Mol Genet, 19(20), 3895-905 (2010) DOI:10.1093/hmg/ddq300
77. M. A. Passini, J. Bu, E. M. Roskelley, A. M. Richards, S. P. Sardi, C. R. O'Riordan, K. W. Klinger, L. S. Shihabuddin and S. H. Cheng: CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. J Clin Invest, 120(4), 1253-64 (2010) DOI:10.1172/JCI41615
78. E. Dominguez, T. Marais, N. Chatauret, S. Benkhelifa-Ziyyat, S. Duque, P. Ravassard, R. Carcenac, S. Astord, A. Pereira de Moura, T. Voit and M. Barkats: Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum Mol Genet, 20(4), 681-93 (2011) DOI:10.1093/hmg/ddq514
79. S. Benkhelifa-Ziyyat, A. Besse, M. Roda, S. Duque, S. Astord, R. Carcenac, T. Marais and M. Barkats: Intramuscular scAAV9-SMN injection mediates widespread gene delivery to the spinal cord and decreases disease severity in SMA mice. Mol Ther, 21(2), 282-90 (2013) DOI:10.1038/mt.2012.261
80. A. K. Bevan, S. Duque, K. D. Foust, P. R. Morales, L. Braun, L. Schmelzer, C. M. Chan, M. McCrate, L. G. Chicoine, B. D. Coley, P. N. Porensky, S. J. Kolb, J. R. Mendell, A. H. Burghes and B. K. Kaspar: Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol Ther, 19(11), 1971-80 (2011) DOI:10.1038/mt.2011.157
81. T. Federici, J. S. Taub, G. R. Baum, S. J. Gray, J. C. Grieger, K. A. Matthews, C. R. Handy, M. A. Passini, R. J. Samulski and N. M. Boulis: Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs. Gene Ther, 19(8), 852-9 (2012) DOI:10.1038/gt.2011.130
82. S. J. Gray, S. Nagabhushan Kalburgi, T. J. McCown and R. Jude Samulski: Global CNS gene delivery and evasion of anti-AAVneutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther, 20(4), 450-9 (2013) DOI:10.1038/gt.2012.101
83. B. Dong, H. Nakai and W. Xiao: Characterization of genome integrity for oversized recombinant AAV vector. Mol Ther, 18(1), 87-92 (2010) DOI:10.1038/mt.2009.258
84. Y. Lai, Y. Yue and D. Duan: Evidence for the failure of adeno-associated virus serotype 5 to package a viral genome > or = 8.2. kb. Mol Ther, 18(1), 75-9 (2010) DOI:10.1038/mt.2009.256
85. Z. Wu, H. Yang and P. Colosi: Effect of genome size on AAV vector packaging. Mol Ther, 18(1), 80-6 (2010) DOI:10.1038/mt.2009.255
86. J. C. Grieger and R. J. Samulski: Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps. J Virol, 79(15), 9933-44 (2005) DOI:10.1128/JVI.79.15.9933-9944.2005
87. Z. Yan, Y. Zhang, D. Duan and J. F. Engelhardt: Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. Proc Natl Acad Sci U S A, 97(12), 6716-21 (2000) DOI:10.1073/pnas.97.12.6716
88. J. Yang, W. Zhou, Y. Zhang, T. Zidon, T. Ritchie and J. F. Engelhardt: Concatamerization of adeno-associated virus circular genomes occurs through intermolecular recombination. J Virol, 73(11), 9468-77 (1999)
89. S. J. Reich, A. Auricchio, M. Hildinger, E. Glover, A. M. Maguire, J. M. Wilson and J. Bennett: Efficient trans-splicing in the retina expands the utility of adeno-associated virus as a vector for gene therapy. Hum Gene Ther, 14(1), 37-44 (2003) DOI:10.1089/10430340360464697
90. I. Trapani, P. Colella, A. Sommella, C. Iodice, G. Cesi, S. de Simone, E. Marrocco, S. Rossi, M. Giunti, A. Palfi, G. J. Farrar, R. Polishchuk and A. Auricchio: Effective delivery of large genes to the retina by dual AAV vectors. EMBO Mol Med, 6(2), 194-211 (2014)
91. Y. Lai, Y. Yue, M. Liu, A. Ghosh, J. F. Engelhardt, J. S. Chamberlain and D. Duan: Efficient in vivo gene expression by transsplicing adeno-associated viral vectors. Nat Biotechnol, 23(11), 1435-9 (2005) DOI:10.1038/nbt1153
92. A. Ghosh, Y. Yue, J. H. Shin and D. Duan: Systemic Trans-splicing adeno-associated viral delivery efficiently transduces the heart of adult mdx mouse, a model for duchenne muscular dystrophy. Hum Gene Ther, 20(11), 1319-28 (2009) DOI:10.1089/hum.2009.058
93. T. Koo, L. Popplewell, T. Athanasopoulos and G. Dickson: Triple trans-splicing adeno-associated virus vectors capable of transferring the coding sequence for fulllength dystrophin protein into dystrophic mice. Hum Gene Ther, 25(2), 98-108 (2014) DOI:10.1089/hum.2013.164
94. L. Zhong, B. Li, G. Jayandharan, C. S. Mah, L. Govindasamy, M. Agbandje-McKenna, R. W. Herzog, K. A. Weigel-Van Aken, J. A. Hobbs, S. Zolotukhin, N. Muzyczka and A. Srivastava: Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression. Virology, 381(2), 194-202 (2008) DOI:10.1016/j.virol.2008.08.027
95. L. Zhong, B. Li, C. S. Mah, L. Govindasamy, M. Agbandje-McKenna, M. Cooper, R. W. Herzog, I. Zolotukhin, K. H. Warrington, Jr., K. A. Weigel-Van Aken, J. A. Hobbs, S. Zolotukhin, N. Muzyczka and A. Srivastava: Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci U S A, 105(22), 7827-32 (2008) DOI:10.1073/pnas.0802866105
96. G. V. Aslanidi, A. E. Rivers, L. Ortiz, L. Song, C. Ling, L. Govindasamy, K. Van Vliet, M. Tan, M. Agbandje-McKenna and A. Srivastava: Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS One, 8(3), e59142 (2013) DOI:10.1371/journal.pone.0059142
97. F. Mingozzi and K. A. High: Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet, 12(5), 341-55 (2011) DOI:10.1038/nrg2988
98. S. Boutin, V. Monteilhet, P. Veron, C. Leborgne, O. Benveniste, M. F. Montus and C. Masurier: Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther, 21(6), 704-12 (2010) DOI:10.1089/hum.2009.182
99. M. Moskalenko, L. Chen, M. van Roey, B. A. Donahue, R. O. Snyder, J. G. McArthur and S. D. PaTel: Epitope mapping of human antiadeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. J Virol, 74(4), 1761-6 (2000) DOI:10.1128/JVI.74.4.1761-1766.2000
100. K. Rapti, V. Louis-Jeune, E. Kohlbrenner, K. Ishikawa, D. Ladage, S. Zolotukhin, R. J. Hajjar and T. Weber: Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models. Mol Ther, 20(1), 73-83 (2012) DOI:10.1038/mt.2011.177
101. R. S. Selot, S. Hareendran and G. R. Jayandharan: Developing immunologically inert adeno-associated virus (AAV) vectors for gene therapy: possibilities and limitations. Curr Pharm Biotechnol, 14(12), 1072-82 (2014) DOI:10.2174/1389201015666140327141710
102. R. Calcedo, L. H. Vandenberghe, G. Gao, J. Lin and J. M. Wilson: Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis, 199(3), 381-90 (2009) DOI:10.1086/595830
103. S. L. Farkas, Z. Zadori, M. Benko, S. Essbauer, B. Harrach and P. Tijssen: A parvovirus isolated from royal python (Python regius) is a member of the genus Dependovirus. J Gen Virol, 85(Pt 3), 555-61 (2004) DOI:10.1099/vir.0.19616-0
104. J. Qiu, F. Cheng and D. PinTel: Molecular characterization of caprine adeno-associated virus (AAV-Go.1) reveals striking similarity to human AAV5. Virology, 356(1-2), 208-16 (2006) DOI:10.1016/j.virol.2006.07.024
105. Y. Li, X. Ge, C. C. Hon, H. Zhang, P. Zhou, Y. Zhang, Y. Wu, L. F. Wang and Z. Shi: Prevalence and genetic diversity of adenoassociated viruses in bats from China. J Gen Virol, 91(Pt 10), 2601-9 (2010) DOI:10.1099/vir.0.020032-0
106. L. Li, T. Shan, C. Wang, C. Cote, J. Kolman, D. Onions, F. M. Gulland and E. Delwart: The fecal viral flora of California sea lions. J Virol, 85(19), 9909-17 (2011) DOI:10.1128/JVI.05026-11
107. L. M. Drouin and M. Agbandje-McKenna: Adeno-associated virus structural biology as a tool in vector development. Future Virol, 8(12), 1183-1199 (2013) DOI: 10.2217/fvl.13.112
108. L. Yang, J. Jiang, L. M. Drouin, M. Agbandje-McKenna, C. Chen, C. Qiao, D. Pu, X. Hu, D. Z. Wang, J. Li and X. Xiao: A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl Acad Sci U S A, 106(10), 3946-51 (2009) DOI:10.1073/pnas.0813207106
109. A. Asokan, J. C. Conway, J. L. Phillips, C. Li, J. Hegge, R. Sinnott, S. Yadav, N. DiPrimio, H. J. Nam, M. Agbandje-McKenna, S. McPhee, J. Wolff and R. J. Samulski: Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Nat Biotechnol, 28(1), 79-82 (2010) DOI:10.1038/nbt.1599
110. N. Pulicherla, S. Shen, S. Yadav, K. Debbink, L. Govindasamy, M. Agbandje-McKenna and A. Asokan: Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer. Mol Ther, 19(6), 1070-8 (2011) DOI:10.1038/mt.2011.22
111. A. Vulin, I. Barthelemy, A. Goyenvalle, J. L. Thibaud, C. Beley, G. Griffith, R. Benchaouir, M. le Hir, Y. Unterfinger, S. Lorain, P. Dreyfus, T. Voit, P. Carlier, S. Blot and L. Garcia: Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping. Mol Ther, 20(11), 2120-33 (2012) DOI: 10.1038/mt.2012.181
112. E. P. Hoffman: Skipping toward personalized molecular medicine. N Engl J Med, 357(26), 2719-22 (2007) DOI:10.1056/NEJMe0707795
113. S. Lorain, D. A. Gross, A. Goyenvalle, O. Danos, J. Davoust and L. Garcia: Transient immunomodulation allows repeated injections of AAV1 and correction of muscular dystrophy in multiple muscles. Mol Ther, 16(3), 541-7 (2008) DOI:10.1038/sj.mt.6300377
114. W. Xiao, N. Chirmule, S. C. Berta, B. McCullough, G. Gao and J. M. Wilson: Gene therapy vectors based on adeno-associated virus type 1. J Virol, 73(5), 3994-4003 (1999)
115. C. L. Halbert, E. A. Rutledge, J. M. Allen, D. W. Russell and A. D. Miller: Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes. J Virol, 74(3), 1524-32 (2000) DOI:10.1128/JVI.74.3.1524-1532.2000
116. M. Hildinger, A. Auricchio, G. Gao, L. Wang, N. Chirmule and J. M. Wilson: Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene transfer. J Virol, 75(13), 6199-203 (2001) DOI: 10.1128/JVI.75.13.6199-6203.2001
117. C. Riviere, O. Danos and A. M. Douar: Longterm expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice. Gene Ther, 13(17), 1300-8 (2006) DOI:10.1038/sj.gt.3302766
118. P. C. Zamecnik and M. L. Stephenson: Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci U S A, 75(1), 280-4 (1978) DOI:10.1073/pnas.75.1.280
119. E. R. Rayburn and R. Zhang: Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible? Drug Discov Today, 13(11-12), 513-21 (2008) DOI:10.1016/j.drudis.2008.03.014
120. Z. A. Pramono, Y. Takeshima, H. Alimsardjono, A. Ishii, S. Takeda and M. Matsuo: Induction of exon skipping of the dystrophin transcript in lymphoblastoid cells by transfecting an antisense oligodeoxynucleotide complementary to an exon recognition sequence. Biochem Biophys Res Commun, 226(2), 445-9 (1996) DOI:10.1006/bbrc.1996.1375
121. M. G. Dunckley, M. Manoharan, P. Villiet, I. C. Eperon and G. Dickson: Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. Hum Mol Genet, 7(7), 1083-90 (1998) DOI:10.1093/hmg/7.7.1083
122. Q. L. Lu, C. J. Mann, F. Lou, G. Bou-Gharios, G. E. Morris, S. A. Xue, S. Fletcher, T. A. Partridge and S. D. Wilton: Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med, 9(8), 1009-14 (2003) DOI:10.1038/nm897
123. S. Fletcher, K. Honeyman, A. M. Fall, P. L. Harding, R. D. Johnsen and S. D. Wilton: Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide. J Gene Med, 8(2), 207-16 (2006) DOI:10.1002/jgm.838
124. S. Fletcher, K. Honeyman, A. M. Fall, P. L. Harding, R. D. Johnsen, J. P. Steinhaus, H. M. Moulton, P. L. Iversen and S. D. Wilton: Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse. Mol Ther, 15(9), 1587-92 (2007) DOI:10.1038/sj.mt.6300245
125. G. D. Ivanova, A. Arzumanov, R. Abes, H. Yin, M. J. Wood, B. Lebleu and M. J. Gait: Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle. Nucleic Acids Res, 36(20), 6418-28 (2008) DOI:10.1093/nar/gkn671
126. H. Yin, Q. Lu and M. Wood: Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice. Mol Ther, 16(1), 38-45 (2008) DOI:10.1038/sj.mt.6300329
127. Q. L. Lu, A. Rabinowitz, Y. C. Chen, T. Yokota, H. Yin, J. Alter, A. Jadoon, G. Bou-Gharios and T. Partridge: Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci U S A, 102(1), 198-203 (2005) DOI:10.1073/pnas.0406700102
128. H. Heemskerk, C. de Winter, P. van Kuik, N. Heuvelmans, P. Sabatelli, P. Rimessi, P. Braghetta, G. J. van Ommen, S. de Kimpe, A. Ferlini, A. Aartsma-Rus and J. C. van Deutekom: Preclinical PK and PD studies on 2′-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model. Mol Ther, 18(6), 1210-7 (2010) DOI:10.1038/mt.2010.72
129. J. Alter, F. Lou, A. Rabinowitz, H. Yin, J. Rosenfeld, S. D. Wilton, T. A. Partridge and Q. L. Lu: Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med, 12(2), 175-7 (2006) DOI:10.1038/nm1345
130. B. Wu, P. Lu, E. Benrashid, S. Malik, J. Ashar, T. J. Doran and Q. L. Lu: Dose-dependent restoration of dystrophin expression in cardiac muscle of dystrophic mice by systemically delivered morpholino. Gene Ther, 17(1), 132-40 (2010) DOI:10.1038/gt.2009.120
131. A. Malerba, P. S. Sharp, I. R. Graham, V. Arechavala-Gomeza, K. Foster, F. Muntoni, D. J. Wells and G. Dickson: Chronic systemic therapy with low-dose morpholino oligomers ameliorates the pathology and normalizes locomotor behavior in mdx mice. Mol Ther, 19(2), 345-54 (2011) DOI:10.1038/mt.2010.261
132. T. Yokota, Q. L. Lu, T. Partridge, M. Kobayashi, A. Nakamura, S. Takeda and E. Hoffman: Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol, 65(6), 667-76 (2009) DOI:10.1002/ana.21627
133. A. Aartsma-Rus, I. Fokkema, J. Verschuuren, I. Ginjaar, J. van Deutekom, G. J. van Ommen and J. T. den Dunnen: Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat, 30(3), 293-9 (2009) DOI:10.1002/humu.20918
134. J. C. van Deutekom, A. A. Janson, I. B. Ginjaar, W. S. Frankhuizen, A. Aartsma-Rus, M. Bremmer-Bout, J. T. den Dunnen, K. Koop, A. J. van der Kooi, N. M. Goemans, S. J. de Kimpe, P. F. Ekhart, E. H. Venneker, G. J. Platenburg, J. J. Verschuuren and G. J. van Ommen: Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med, 357(26), 2677-86 (2007) DOI:10.1056/NEJMoa073108
135. N. M. Goemans, M. Tulinius, J. T. van den Akker, B. E. Burm, P. F. Ekhart, N. Heuvelmans, T. Holling, A. A. Janson, G. J. Platenburg, J. A. Sipkens, J. M. Sitsen, A. Aartsma-Rus, G. J. van Ommen, G. Buyse, N. Darin, J. J. Verschuuren, G. V. Campion, S. J. de Kimpe and J. C. van Deutekom: Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med, 364(16), 1513-22 (2011) DOI:10.1056/NEJMoa1011367
136. T. Voit, H. Topaloglu, V. Straub, F. Muntoni, N. Deconinck, G. Campion, S. J. De Kimpe, M. Eagle, M. Guglieri, S. Hood, L. Liefaard, A. Lourbakos, A. Morgan, J. Nakielny, N. Quarcoo, V. Ricotti, K. Rolfe, L. Servais, C. Wardell, R. Wilson, P. Wright and J. E. Kraus: Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol, 13(10), 987-96 (2014) DOI:10.1016/S1474-4422(14) 70195-4
137. Q. L. Lu, S. Cirak and T. Partridge: What Can We Learn From Clinical Trials of Exon Skipping for DMD? Mol Ther Nucleic Acids, 3, e152 (2014) DOI:10.1038/mtna.2014.6
138. M. Kinali, V. Arechavala-Gomeza, L. Feng, S. Cirak, D. Hunt, C. Adkin, M. Guglieri, E. Ashton, S. Abbs, P. Nihoyannopoulos, M. E. Garralda, M. Rutherford, C. McCulley, L. Popplewell, I. R. Graham, G. Dickson, M. J. Wood, D. J. Wells, S. D. Wilton, R. Kole, V. Straub, K. Bushby, C. Sewry, J. E. Morgan and F. Muntoni: Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebocontrolled, dose-escalation, proof-of-concept study. Lancet Neurol, 8(10), 918-28 (2009) DOI:10.1016/S1474-4422(09) 70211-X
139. S. Cirak, V. Arechavala-Gomeza, M. Guglieri, L. Feng, S. Torelli, K. Anthony, S. Abbs, M. E. Garralda, J. Bourke, D. J. Wells, G. Dickson, M. J. Wood, S. D. Wilton, V. Straub, R. Kole, S. B. Shrewsbury, C. Sewry, J. E. Morgan, K. Bushby and F. Muntoni: Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, doseescalation study. Lancet, 378(9791), 595-605 (2011) DOI:10.1016/S0140-6736(11) 60756-3
140. J. R. Mendell, L. R. Rodino-Klapac, Z. Sahenk, K. Roush, L. Bird, L. P. Lowes, L. Alfano, A. M. Gomez, S. Lewis, J. Kota, V. Malik, K. Shontz, C. M. Walker, K. M. Flanigan, M. Corridore, J. R. Kean, H. D. Allen, C. Shilling, K. R. Melia, P. Sazani, J. B. Saoud and E. M. Kaye: Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol, 74(5), 637-47 (2013) DOI:10.1002/ana.23982
141. A. Goyenvalle, A. Vulin, F. Fougerousse, F. Leturcq, J. C. Kaplan, L. Garcia and O. Danos: Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science, 306(5702), 1796-9 (2004) DOI:10.1126/science.1104297
142. M. A. Denti, A. Rosa, G. D'Antona, O. Sthandier, F. G. De Angelis, C. Nicoletti, M. Allocca, O. Pansarasa, V. Parente, A. Musaro, A. Auricchio, R. Bottinelli and I. Bozzoni: Bodywide gene therapy of Duchenne muscular dystrophy in the mdx mouse model. Proc Natl Acad Sci U S A, 103(10), 3758-63 (2006) DOI:10.1073/pnas.0508917103
143. F. G. De Angelis, O. Sthandier, B. Berarducci, S. Toso, G. Galluzzi, E. Ricci, G. Cossu and I. Bozzoni: Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin premRNA induce exon skipping and restoration of a dystrophin synthesis in Delta 48-50 DMD cells. Proc Natl Acad Sci U S A, 99(14), 9456-61 (2002) DOI:10.1073/pnas.142302299
144. C. Grimm, B. Stefanovic and D. Schumperli: The low abundance of U7 snRNA is partly determined by its Sm binding site. Embo J, 12(3), 1229-38 (1993)
145. A. Goyenvalle, J. Wright, A. Babbs, V. Wilkins, L. Garcia and K. E. Davies: Engineering Multiple U7snRNA Constructs to Induce Single and Multiexon-skipping for Duchenne Muscular Dystrophy. Mol Ther (2012) DOI:10.1038/mt.2012.26
146. C. L. Lorson, E. Hahnen, E. J. Androphy and B. Wirth: A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci U S A, 96(11), 6307-11 (1999) DOI:10.1073/pnas.96.11.6307
147. U. R. Monani, C. L. Lorson, D. W. Parsons, T. W. Prior, E. J. Androphy, A. H. Burghes and J. D. McPherson: A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum Mol Genet, 8(7), 1177-83 (1999) DOI:10.1093/hmg/8.7.1177
148. L. Cartegni and A. R. Krainer: Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat Genet, 30(4), 377-84 (2002) DOI:10.1038/ng854
149. L. Cartegni, M. L. Hastings, J. A. Calarco, E. de Stanchina and A. R. Krainer: Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2. Am J Hum Genet, 78(1), 63-77 (2006) DOI:10.1086/498853
150. A. J. Matlin, F. Clark and C. W. Smith: Understanding alternative splicing: towards a cellular code. Nat Rev Mol Cell Biol, 6(5), 386-98 (2005) DOI:10.1038/nrm1645
151. T. Kashima and J. L. Manley: A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy. Nat Genet, 34(4), 460-3 (2003) DOI:10.1038/ng1207
152. N. N. Singh, E. J. Androphy and R. N. Singh: An extended inhibitory context causes skipping of exon 7 of SMN2 in spinal muscular atrophy. Biochem Biophys Res Commun, 315(2), 381-8 (2004) DOI:10.1016/j.bbrc.2004.01.067
153. N. N. Singh, R. N. Singh and E. J. Androphy: Modulating role of RNA structure in alternative splicing of a critical exon in the spinal muscular atrophy genes. Nucleic Acids Res, 35(2), 371-89 (2007) DOI:10.1093/nar/gkl1050
154. N. K. Singh, N. N. Singh, E. J. Androphy and R. N. Singh: Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron. Mol Cell Biol, 26(4), 1333-46 (2006) DOI:10.1128/MCB.26.4.1333-1346.2006
155. L. Pellizzoni, B. Charroux and G. Dreyfuss: SMN mutants of spinal muscular atrophy patients are defective in binding to snRNP proteins. Proc Natl Acad Sci U S A, 96(20), 11167-72 (1999) DOI:10.1073/pnas.96.20.11167
156. N. N. Singh, E. J. Androphy and R. N. Singh: In vivo selection reveals combinatorial controls that define a critical exon in the spinal muscular atrophy genes. Rna, 10(8), 1291-305 (2004) DOI:10.1261/rna.7580704
157. S. R. Lim and K. J. HerTel: Modulation of survival motor neuron pre-mRNA splicing by inhibition of alternative 3′ splice site pairing. J Biol Chem, 276(48), 45476-83 (2001) DOI:10.1074/jbc.M107632200
158. L. Cartegni and A. R. Krainer: Correction of disease-associated exon skipping by synthetic exon-specific activators. Nat Struct Biol, 10(2), 120-5 (2003) DOI:10.1038/nsb887
159. L. A. Skordis, M. G. Dunckley, B. Yue, I. C. Eperon and F. Muntoni: Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proc Natl Acad Sci U S A, 100(7), 4114-9 (2003) DOI:10.1073/pnas.0633863100
160. A. Dickson, E. Osman and C. L. Lorson: A negatively acting bifunctional RNA increases survival motor neuron both in vitro and in vivo. Hum Gene Ther, 19(11), 1307-15 (2008) DOI:10.1089/hum.2008.067
161. T. D. Baughan, A. Dickson, E. Y. Osman and C. L. Lorson: Delivery of bifunctional RNAs that target an intronic repressor and increase SMN levels in an animal model of spinal muscular atrophy. Hum Mol Genet, 18(9), 1600-11 (2009) DOI:10.1093/hmg/ddp076
162. E. Y. Osman, P. F. Yen and C. L. Lorson: Bifunctional RNAs targeting the intronic splicing silencer N1 increase SMN levels and reduce disease severity in an animal model of spinal muscular atrophy. Mol Ther, 20(1), 119-26 (2012) DOI:10.1038/mt.2011.232
163. Y. Hua, T. A. Vickers, B. F. Baker, C. F. Bennett and A. R. Krainer: Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon. PLoS Biol, 5(4), e73 (2007) DOI:10.1371/journal.pbio.0050073
164. Y. Hua, K. Sahashi, G. Hung, F. Rigo, M. A. Passini, C. F. Bennett and A. R. Krainer: Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev, 24(15), 1634-44 (2010) DOI:10.1101/gad.1941310
165. Y. Hua, K. Sahashi, F. Rigo, G. Hung, G. Horev, C. F. Bennett and A. R. Krainer: Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature, 478(7367), 123-6 (2011) DOI:10.1038/nature10485
166. T. H. Coady and C. L. Lorson: SMN in spinal muscular atrophy and snRNP biogenesis. Wiley Interdiscip Rev RNA, 2(4), 546-64 (2011) DOI:10.1002/wrna.76
167. P. N. Porensky, C. Mitrpant, V. L. McGovern, A. K. Bevan, K. D. Foust, B. K. Kaspar, S. D. Wilton and A. H. Burghes: A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse. Hum Mol Genet, 21(7), 1625-38 (2012) DOI:10.1093/hmg/ddr600
168. H. Zhou, N. Janghra, C. Mitrpant, R. L. Dickinson, K. Anthony, L. Price, I. C. Eperon, S. D. Wilton, J. Morgan and F. Muntoni: A novel morpholino oligomer targeting ISS-N1 improves rescue of severe spinal muscular atrophy transgenic mice. Hum Gene Ther, 24(3), 331-42 (2013) DOI:10.1089/hum.2012.211
169. E. Y. Osman, M. R. Miller, K. L. Robbins, A. M. Lombardi, A. K. Atkinson, A. J. Brehm and C. L. Lorson: Morpholino antisense oligonucleotides targeting intronic repressor Element1 improve phenotype in SMA mouse models. Hum Mol Genet, 23(18), 4832-45 (2014) DOI:10.1093/hmg/ddu198
170. C. Madocsai, S. R. Lim, T. Geib, B. J. Lam and K. J. HerTel: Correction of SMN2 Pre-mRNA splicing by antisense U7 small nuclear RNAs. Mol Ther, 12(6), 1013-22 (2005) DOI:10.1016/j.ymthe.2005.08.022
171. R. Scholl, J. Marquis, K. Meyer and D. Schumperli: Spinal muscular atrophy: position and functional importance of the branch site preceding SMN exon 7. RNA Biol, 4(1), 34-7 (2007) DOI:10.4161/rna.4.1.4534
172. R. Nlend Nlend, K. Meyer and D. Schumperli: Repair of pre-mRNA splicing: prospects for a therapy for spinal muscular atrophy. RNA Biol, 7(4), 430-40 (2010) DOI:10.4161/rna.7.4.12206
173. J. Marquis, K. Meyer, L. Angehrn, S. S. Kampfer, B. Rothen-Rutishauser and D. Schumperli: Spinal muscular atrophy: SMN2 pre-mRNA splicing corrected by a U7 snRNA derivative carrying a splicing enhancer sequence. Mol Ther, 15(8), 1479-86 (2007) DOI:10.1038/sj.mt.6300200
174. K. Meyer, J. Marquis, J. Trub, R. Nlend Nlend, S. Verp, M. D. Ruepp, H. Imboden, I. Barde, D. Trono and D. Schumperli: Rescue of a severe mouse model for spinal muscular atrophy by U7 snRNA-mediated splicing modulation. Hum Mol Genet, 18(3), 546-55 (2009) DOI:10.1093/hmg/ddn382
175. T. Voigt, K. Meyer, O. Baum and D. Schumperli: Ultrastructural changes in diaphragm neuromuscular junctions in a severe mouse model for Spinal Muscular Atrophy and their prevention by bifunctional U7 snRNA correcting SMN2 splicing. Neuromuscul Disord, 20(11), 744-52 (2010) DOI:10.1016/j.nmd.2010.06.010
176. M. Mahadevan, C. Tsilfidis, L. Sabourin, G. Shutler, C. Amemiya, G. Jansen, C. Neville, M. Narang, J. Barcelo, K. O'Hoy and et al.: Myotonic dystrophy mutation: an unstable CTG repeat in the 3′ untranslated region of the gene. Science, 255(5049), 1253-5 (1992) DOI:10.1126/science.1546325
177. J. W. Day and L. P. Ranum: Genetics and molecular pathogenesis of the myotonic dystrophies. Curr Neurol Neurosci Rep, 5(1), 55-9 (2005) DOI:10.1007/s11910-005-0024-1
178. V. Yotova, D. Labuda, E. Zietkiewicz, D. Gehl, A. Lovell, J. F. Lefebvre, S. Bourgeois, E. Lemieux-Blanchard, M. Labuda, H. Vezina, L. Houde, M. Tremblay, B. Toupance, E. Heyer, T. J. Hudson and C. Laberge: Anatomy of a founder effect: myotonic dystrophy in Northeastern Quebec. Hum Genet, 117(2-3), 177-87 (2005) DOI:10.1007/s00439-005-1298-8
179. J. D. Brook, M. E. McCurrach, H. G. Harley, A. J. Buckler, D. Church, H. Aburatani, K. Hunter, V. P. Stanton, J. P. Thirion, T. Hudson and et al.: Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member. Cell, 68(4), 799-808 (1992) DOI:10.1016/0092-8674(92) 90154-5
180. C. L. Liquori, K. Ricker, M. L. Moseley, J. F. Jacobsen, W. Kress, S. L. Naylor, J. W. Day and L. P. Ranum: Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science, 293(5531), 864-7 (2001) DOI:10.1126/science.1062125
181. T. Ashizawa and P. S. Sarkar: Myotonic dystrophy types 1 and 2. Handb Clin Neurol, 101, 193-237 (2011) DOI:10.1016/B978-0-08-045031-5.00015-3
182. J. W. Day, K. Ricker, J. F. Jacobsen, L. J. Rasmussen, K. A. Dick, W. Kress, C. Schneider, M. C. Koch, G. J. Beilman, A. R. Harrison, J. C. Dalton and L. P. Ranum: Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology, 60(4), 657-64 (2003) DOI:10.1212/01.WNL.0000054481.84978.F9
183. L. P. Ranum and J. W. Day: Myotonic dystrophy: RNA pathogenesis comes into focus. Am J Hum Genet, 74(5), 793-804 (2004) DOI:10.1086/383590
184. B. Udd and R. Krahe: The myotonic dystrophies: molecular, clinical, and therapeutic challenges. Lancet Neurol, 11(10), 891-905 (2012) DOI:10.1016/S1474-4422(12) 70204-1
185. A. Mankodi, C. R. Urbinati, Q. P. Yuan, R. T. Moxley, V. Sansone, M. Krym, D. Henderson, M. Schalling, M. S. Swanson and C. A. Thornton: Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2. Hum Mol Genet, 10(19), 2165-70 (2001) DOI:10.1093/hmg/10.19.2165
186. J. W. Miller, C. R. Urbinati, P. Teng-Umnuay, M. G. Stenberg, B. J. Byrne, C. A. Thornton and M. S. Swanson: Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy. Embo J, 19(17), 4439-48 (2000) DOI:10.1093/emboj/19.17.4439
187. A. V. Philips, L. T. Timchenko and T. A. Cooper: Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. Science, 280(5364), 737-41 (1998) DOI:10.1126/science.280.5364.737
188. J. D. Lueck, C. Lungu, A. Mankodi, R. J. Osborne, S. L. Welle, R. T. Dirksen and C. A. Thornton: Chloride channelopathy in myotonic dystrophy resulting from loss of posttranscriptional regulation for CLCN1. Am J Physiol Cell Physiol, 292(4), C1291-7 (2007) DOI:10.1152/ajpcell.00336.2006
189. C. Fugier, A. F. Klein, C. Hammer, S. Vassilopoulos, Y. Ivarsson, A. Toussaint, V. Tosch, A. Vignaud, A. Ferry, N. Messaddeq, Y. Kokunai, R. Tsuburaya, P. de la Grange, D. Dembele, V. Francois, G. Precigout, C. Boulade-Ladame, M. C. Hummel, A. Lopez de Munain, N. Sergeant, A. Laquerriere, C. Thibault, F. Deryckere, D. Auboeuf, L. Garcia, P. Zimmermann, B. Udd, B. Schoser, M. P. Takahashi, I. Nishino, G. Bassez, J. Laporte, D. Furling and N. Charlet-Berguerand: Misregulated alternative splicing of BIN1 is associated with T tubule alterations and muscle weakness in myotonic dystrophy. Nat Med, 17(6), 720-5 (2011) DOI:10.1038/nm.2374
190. W. Dansithong, S. Paul, L. Comai and S. Reddy: MBNL1 is the primary determinant of focus formation and aberrant insulin receptor splicing in DM1. J Biol Chem, 280(7), 5773-80 (2005) DOI:10.1074/jbc.M410781200
191. N. M. Kuyumcu-Martinez, G. S. Wang and T. A. Cooper: Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Mol Cell, 28(1), 68-78 (2007) DOI:10.1016/j.molcel.2007.07.027
192. G. S. Wang, D. L. Kearney, M. De Biasi, G. Taffet and T. A. Cooper: Elevation of RNAbinding protein CUGBP1 is an early event in an inducible heart-specific mouse model of myotonic dystrophy. J Clin Invest, 117(10), 2802-11 (2007) DOI:10.1172/JCI32308
193. Z. Gao and T. A. Cooper: Antisense oligonucleotides: rising stars in eliminating RNA toxicity in myotonic dystrophy. Hum Gene Ther, 24(5), 499-507 (2013) DOI:10.1089/hum.2012.212
194. T. M. Wheeler, K. Sobczak, J. D. Lueck, R. J. Osborne, X. Lin, R. T. Dirksen and C. A. Thornton: Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science, 325(5938), 336-9 (2009) DOI:10.1126/science.1173110
195. S. A. Mulders, W. J. van den Broek, T. M. Wheeler, H. J. Croes, P. van Kuik-Romeijn, S. J. de Kimpe, D. Furling, G. J. Platenburg, G. Gourdon, C. A. Thornton, B. Wieringa and D. G. Wansink: Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc Natl Acad Sci U S A, 106(33), 13915-20 (2009) DOI:10.1073/pnas.0905780106
196. A. J. Leger, L. M. Mosquea, N. P. Clayton, I. H. Wu, T. Weeden, C. A. Nelson, L. Phillips, E. Roberts, P. A. Piepenhagen, S. H. Cheng and B. M. Wentworth: Systemic delivery of a Peptide-linked morpholino oligonucleotide neutralizes mutant RNA toxicity in a mouse model of myotonic dystrophy. Nucleic Acid Ther, 23(2), 109-17 (2013)
197. J. E. Lee, C. F. Bennett and T. A. Cooper: RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1. Proc Natl Acad Sci U S A, 109(11), 4221-6 (2012) DOI:10.1073/pnas.1117019109
198. T. M. Wheeler, A. J. Leger, S. K. Pandey, A. R. MacLeod, M. Nakamori, S. H. Cheng, B. M. Wentworth, C. F. Bennett and C. A. Thornton: Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature, 488(7409), 111-5 (2012) DOI:10.1038/nature11362
199. V. Francois, A. F. Klein, C. Beley, A. Jollet, C. Lemercier, L. Garcia and D. Furling: Selective silencing of mutated mRNAs in DM1 by using modified hU7-snRNAs. Nat Struct Mol Biol, 18(1), 85-7 (2011) DOI:10.1038/nsmb.1958
200. T. Yokota, Q. L. Lu, T. Partridge, M. Kobayashi, A. Nakamura, S. Takeda and E. Hoffman: Efficacy of systemic morpholino exonskipping in duchenne dystrophy dogs. Ann Neurol (2009) DOI:10.1002/ana.21627
201. H. A. Heemskerk, C. L. de Winter, S. J. de Kimpe, P. van Kuik-Romeijn, N. Heuvelmans, G. J. Platenburg, G. J. van Ommen, J. C. van Deutekom and A. Aartsma-Rus: In vivo comparison of 2′-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J Gene Med, 11(3), 257-66 (2009) DOI:10.1002/jgm.1288
202. B. Wu, P. Lu, E. Benrashid, S. Malik, J. Ashar, T. J. Doran and Q. L. Lu: Dose-dependent restoration of dystrophin expression in cardiac muscle of dystrophic mice by systemically delivered morpholino. Gene Ther, 17(1), 132-40 DOI:10.1038/gt.2009.120
203. H. Yin, H. M. Moulton, Y. Seow, C. Boyd, J. Boutilier, P. Iverson and M. J. Wood: Cellpenetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum Mol Genet, 17(24), 3909-18 (2008) DOI:10.1093/hmg/ddn293
204. N. Jearawiriyapaisarn, H. M. Moulton, P. Sazani, R. Kole and M. S. Willis: Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers. Cardiovasc Res, 85(3), 444-53 DOI:10.1093/cvr/cvp335
205. B. Wu, H. M. Moulton, P. L. Iversen, J. Jiang, J. Li, J. Li, C. F. Spurney, A. Sali, A. D. Guerron, K. Nagaraju, T. Doran, P. Lu, X. Xiao and Q. L. Lu: Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc Natl Acad Sci U S A, 105(39), 14814-9 (2008) DOI:10.1073/pnas.0805676105
206. H. M. Moulton and J. D. Moulton: Morpholinos and their peptide conjugates: Therapeutic promise and challenge for Duchenne muscular dystrophy. Biochim Biophys Acta
207. A. Goyenvalle, G. Griffith, A. Babbs, S. ElAndaloussi, K. Ezzat, A. Avril, B. Dugovic, R. Chaussenot, A. Ferry, T. Voit, H. Amthor, C. Bühr, S. Schürch, M.J.A. Wood, K.E. Davies, C. Vaillend, C. Leumann and L. Garcia: Functional correction in mouse model of muscular dystrophy using exon skipping tricyclo-DNA oligomers. Nat Med, epub 2 February 2015 DOI:10.1038/nm.3765
208. N. Jearawiriyapaisarn, H. M. Moulton, B. Buckley, J. Roberts, P. Sazani, S. Fucharoen, P. L. Iversen and R. Kole: Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol Ther, 16(9), 1624-9 (2008) DOI:10.1038/mt.2008.120
209. H. Yin, H. M. Moulton, C. Betts, Y. Seow, J. Boutilier, P. L. Iverson and M. J. Wood: A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. Hum Mol Genet, 18(22), 4405-14 (2009) DOI:10.1093/hmg/ddp395
210. C. Betts, A. F. Saleh, A. A. Arzumanov, S. M. Hammond, C. Godfrey, T. Coursindel, M. J. Gait and M. J. Wood: Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment. Mol Ther Nucleic Acids, 1, e38 (2012) DOI:10.1038/mtna.2012.30
211. H. Yin, A. F. Saleh, C. Betts, P. Camelliti, Y. Seow, S. Ashraf, A. Arzumanov, S. Hammond, T. Merritt, M. J. Gait and M. J. Wood: Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. Mol Ther, 19(7), 1295-303 (2011) DOI:10.1038/mt.2011.79
212. J. R. Mendell, L. Rodino-Klapac, Z. Sahenk, V. Malik, B. K. Kaspar, C. M. Walker and K. R. Clark: Gene therapy for muscular dystrophy: lessons learned and path forward. Neurosci Lett, 527(2), 90-9 (2012) DOI:10.1016/j.neulet.2012.04.078
213. S. Arimura, T. Okada, T. Tezuka, T. Chiyo, Y. Kasahara, T. Yoshimura, M. Motomura, N. Yoshida, D. Beeson, S. Takeda and Y. Yamanashi: Neuromuscular disease. DOK7 gene therapy benefits mouse models of diseases characterized by defects in the neuromuscular junction. Science, 345(6203), 1505-8 (2014) DOI:10.1126/science.1250744
214. W. M. van Roon-Mom and A. Aartsma-Rus: Overview on applications of antisensemediated exon skipping. Methods Mol Biol, 867, 79-96 (2012) DOI:10.1007/978-1-61779-767-56
215. P. Disterer, A. Kryczka, Y. Liu, Y. E. Badi, J. J. Wong, J. S. Owen and B. Khoo: Development of therapeutic splice-switching oligonucleotides. Hum Gene Ther, 25(7), 587-98 (2014) DOI:10.1089/hum.2013.234
216. M. Taniguchi-Ikeda, K. Kobayashi, M. Kanagawa, C. C. Yu, K. Mori, T. Oda, A. Kuga, H. Kurahashi, H. O. Akman, S. DiMauro, R. Kaji, T. Yokota, S. Takeda and T. Toda: Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophy. Nature, 478(7367), 127-31 (2011) DOI:10.1038/nature10456
217. Z. Wu, E. Miller, M. Agbandje-McKenna and R. J. Samulski: Alpha2,3 and alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6. J Virol, 80(18), 9093-103 (2006) DOI:10.1128/JVI.00895-06
218. H. Chao, Y. Liu, J. Rabinowitz, C. Li, R. J. Samulski and C. E. Walsh: Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther, 2(6), 619-23 (2000) DOI: 10.1006/mthe.2000.0219
219. C. Wang, C. M. Wang, K. R. Clark and T. J. Sferra: Recombinant AAV serotype 1 transduction efficiency and tropism in the murine brain. Gene Ther, 10(17), 1528-34 (2003) DOI:10.1038/sj.gt.3302011
220. C. Lebherz, A. Maguire, W. Tang, J. Bennett and J. M. Wilson: Novel AAV serotypes for improved ocular gene transfer. J Gene Med, 10(4), 375-82 (2008) DOI:10.1002/jgm.1126
221. S. A. Loiler, Q. Tang, T. Clarke, M. L. Campbell-Thompson, V. Chiodo, W. Hauswirth, P. Cruz, M. Perret-Gentil, M. A. Atkinson, V. K. Ramiya and T. R. Flotte: Localized gene expression following administration of adeno-associated viral vectors via pancreatic ducts. Mol Ther, 12(3), 519-27 (2005) DOI:10.1016/j.ymthe.2005.04.017
222. C. Summerford and R. J. Samulski: Membraneassociated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol, 72(2), 1438-45 (1998)
223. K. Qing, C. Mah, J. Hansen, S. Zhou, V. Dwarki and A. Srivastava: Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med, 5(1), 71-7 (1999) DOI:10.1038/4758
224. M. Richter, A. Iwata, J. Nyhuis, Y. Nitta, A. D. Miller, C. L. Halbert and M. D. Allen: Adeno-associated virus vector transduction of vascular smooth muscle cells in vivo. Physiol Genomics, 2(3), 117-27 (2000)
225. Y. Kashiwakura, K. Tamayose, K. Iwabuchi, Y. Hirai, T. Shimada, K. Matsumoto, T. Nakamura, M. Watanabe, K. Oshimi and H. Daida: Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection. J Virol, 79(1), 609-14 (2005) DOI:10.1128/JVI.79.1.609-614.2005
226. C. S. Manno, A. J. Chew, S. Hutchison, P. J. Larson, R. W. Herzog, V. R. Arruda, S. J. Tai, M. V. Ragni, A. Thompson, M. Ozelo, L. B. Couto, D. G. Leonard, F. A. Johnson, A. McClelland, C. Scallan, E. Skarsgard, A. W. Flake, M. A. Kay, K. A. High and B. Glader: AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood, 101(8), 2963-72 (2003) DOI:10.1182/blood-2002-10-3296
227. B. Akache, D. Grimm, K. Pandey, S. R. Yant, H. Xu and M. A. Kay: The 37/67-kilodalton laminin receptor is a receptor for adenoassociated virus serotypes 8, 2, 3, and 9. J Virol, 80(19), 9831-6 (2006) DOI:10.1128/JVI.00878-06
228. J. S. Bartlett, R. J. Samulski and T. J. McCown: Selective and rapid uptake of adeno-associated virus type 2 in brain. Hum Gene Ther, 9(8), 1181-6 (1998) DOI:10.1089/hum.1998.9.8-1181
229. C. Kurzeder, B. Koppold, G. Sauer, S. Pabst, R. Kreienberg and H. Deissler: CD9 promotes adeno-associated virus type 2 infection of mammary carcinoma cells with low cell surface expression of heparan sulphate proteoglycans. Int J Mol Med, 19(2), 325-33 (2007)
230. S. Takeda, M. Takahashi, H. Mizukami, E. Kobayashi, K. Takeuchi, Y. Hakamata, T. Kaneko, H. Yamamoto, C. Ito, K. Ozawa, K. Ishibashi, T. Matsuzaki, K. Takata, Y. Asano and E. Kusano: Successful gene transfer using adeno-associated virus vectors into the kidney: comparison among adeno-associated virus serotype 1-5 vectors in vitro and in vivo. Nephron Exp Nephrol, 96(4), e119-26 (2004) DOI:10.1159/000077378
231. J. E. Rabinowitz, F. Rolling, C. Li, H. Conrath, W. Xiao, X. Xiao and R. J. Samulski: Crosspackaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol, 76(2), 791-801 (2002) DOI:10.1128/JVI.76.2.791-801.2002
232. S. D. Blackburn, R. A. Steadman and F. B. Johnson: Attachment of adeno-associated virus type 3H to fibroblast growth factor receptor 1. Arch Virol, 151(3), 617-23 (2006) DOI:10.1007/s00705-005-0650-6
233. C. Ling, Y. Lu, J. K. Kalsi, G. R. Jayandharan, B. Li, W. Ma, B. Cheng, S. W. Gee, K. E. McGoogan, L. Govindasamy, L. Zhong, M. Agbandje-McKenna and A. Srivastava: Human hepatocyte growth factor receptor is a cellular coreceptor for adeno-associated virus serotype 3. Hum Gene Ther, 21(12), 1741-7 (2010) DOI:10.1089/hum.2010.075
234. N. Kaludov, K. E. Brown, R. W. Walters, J. Zabner and J. A. Chiorini: Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J Virol, 75(15), 6884-93 (2001) DOI:10.1128/JVI.75.15.6884-6893.2001
235. B. L. Davidson, C. S. Stein, J. A. Heth, I. Martins, R. M. Kotin, T. A. Derksen, J. Zabner, A. Ghodsi and J. A. Chiorini: Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci U S A, 97(7), 3428-32 (2000) DOI:10.1073/pnas.97.7.3428
236. M. Weber, J. Rabinowitz, N. Provost, H. Conrath, S. Folliot, D. Briot, Y. Cherel, P. Chenuaud, J. Samulski, P. Moullier and F. Rolling: Recombinant adeno-associated virus serotype 4 mediates unique and exclusive long-term transduction of retinal pigmented epithelium in rat, dog, and nonhuman primate after subretinal delivery. Mol Ther, 7(6), 774-81 (2003) DOI:10.1016/S1525-0016(03) 00098-4
237. G. Di Pasquale, B. L. Davidson, C. S. Stein, I. Martins, D. Scudiero, A. Monks and J. A. Chiorini: Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med, 9(10), 1306-12 (2003) DOI:10.1038/nm929
238. M. P. Seiler, A. D. Miller, J. Zabner and C. L. Halbert: Adeno-associated virus types 5 and 6 use distinct receptors for cell entry. Hum Gene Ther, 17(1), 10-9 (2006) DOI:10.1089/hum.2006.17.10
239. M. L. Weller, P. Amornphimoltham, M. Schmidt, P. A. Wilson, J. S. Gutkind and J. A. Chiorini: Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6. Nat Med, 16(6), 662-4 (2010) DOI: 10.1038/nm.2145
240. M. J. Blankinship, P. Gregorevic, J. M. Allen, S. Q. Harper, H. Harper, C. L. Halbert, D. A. Miller and J. S. Chamberlain: Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6. Mol Ther, 10(4), 671-8 (2004) DOI:10.1016/j.ymthe.2004.07.016
241. P. Gregorevic, M. J. Blankinship, J. M. Allen, R. W. Crawford, L. Meuse, D. G. Miller, D. W. Russell and J. S. Chamberlain: Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med, 10(8), 828-34 (2004) DOI:10.1038/nm1085
242. C. Zincarelli, S. Soltys, G. Rengo, W. J. Koch and J. E. Rabinowitz: Comparative cardiac gene delivery of adeno-associated virus serotypes 1-9 reveals that AAV6 mediates the most efficient transduction in mouse heart. Clin Transl Sci, 3(3), 81-9 (2010) DOI:10.1111/j.1752-8062.2010.00190.x
243. C. L. Halbert, J. M. Allen and A. D. Miller: Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors. J Virol, 75(14), 6615-24 (2001) DOI:10.1128/JVI.75.14.6615-6624.2001
244. G. P. Gao, M. R. Alvira, L. Wang, R. Calcedo, J. Johnston and J. M. Wilson: Novel adenoassociated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A, 99(18), 11854-9 (2002) DOI:10.1073/pnas.182412299
245. M. Allocca, C. Mussolino, M. Garcia-Hoyos, D. Sanges, C. Iodice, M. Petrillo, L. H. Vandenberghe, J. M. Wilson, V. Marigo, E. M. Surace and A. Auricchio: Novel adeno-associated virus serotypes efficiently transduce murine photoreceptors. J Virol, 81(20), 11372-80 (2007) DOI: 10.1128/JVI.01327-07
246. J. M. Taymans, L. H. Vandenberghe, C. V. Haute, I. Thiry, C. M. Deroose, L. Mortelmans, J. M. Wilson, Z. Debyser and V. Baekelandt: Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. Hum Gene Ther, 18(3), 195-206 (2007) DOI:10.1089/hum.2006.178
247. H. Nakai, S. Fuess, T. A. Storm, S. Muramatsu, Y. Nara and M. A. Kay: Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J Virol, 79(1), 214-24 (2005) DOI:10.1128/JVI.79.1.214-224.2005
248. Z. Wang, T. Zhu, C. Qiao, L. Zhou, B. Wang, J. Zhang, C. Chen, J. Li and X. Xiao: Adenoassociated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol, 23(3), 321-8 (2005) DOI:10.1038/nbt1073
249. S. Shen, K. D. Bryant, S. M. Brown, S. H. Randell and A. Asokan: Terminal N-linked galactose is the primary receptor for adenoassociated virus 9. J Biol Chem, 286(15), 13532-40 (2011) DOI:10.1074/jbc.M110.210922
250. T. Vandendriessche, L. Thorrez, A. Acosta-Sanchez, I. Petrus, L. Wang, L. Ma, D. E. W. L, Y. Iwasaki, V. Gillijns, J. M. Wilson, D. Collen and M. K. Chuah: Efficacy and safety of adenoassociated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy. J Thromb Haemost, 5(1), 16-24 (2007) DOI: 10.1111/j.1538-7836.2006.02220.x
251. Y. Yue, J. H. Shin and D. Duan: Whole body skeletal muscle transduction in neonatal dogs with AAV-9. Methods Mol Biol, 709, 313-29 (2011) DOI:10.1007/978-1-61737-982-621